World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Piñero D, Rapezzi C, Ueda M, Pinto FJ.
Glob Heart. 2023 Oct 26;18(1):59. doi: 10.5334/gh.1262. eCollection 2023.
PMID:37901600
Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis.
Chompoopong P, Mauermann ML, Siddiqi H, Peltier A.
Ann Neurol. 2024 Sep;96(3):423-440. doi: 10.1002/ana.26965. Epub 2024 Jun 24.
PMID:38923548
Transthyretin amyloid cardiomyopathy.
Garcia-Pavia P, Domínguez F, Gonzalez-Lopez E.
Med Clin (Barc). 2021 Feb 12;156(3):126-134. doi: 10.1016/j.medcli.2020.06.064. Epub 2020 Oct 31.
PMID:33138983
Guideline of transthyretin-related hereditary amyloidosis for clinicians.
Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F.
Orphanet J Rare Dis. 2013 Feb 20;8:31. doi: 10.1186/1750-1172-8-31.
PMID:23425518
Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.